CONTEXT: Pituitary tumor-transforming gene (PTTG) is a multifunctional protein involved in several tumorigenic mechanisms, including angiogenesis. PTTG has been shown to promote angiogenesis, a key rate-limiting step in tumor progression, by up-regulation of fibroblast growth factor-2 and vascular endothelial growth factor. OBJECTIVE: To investigate whether PTTG regulates other angiogenic genes in thyroid cells, we performed angiogenesis-specific cDNA arrays after PTTG transfection. Two of the genes [inhibitor of DNA binding-3 (ID3) and thrombospondin-1 (TSP-1)] which showed differential expression in primary thyroid cells were validated in vitro and in vivo. RESULTS: TSP-1 showed a 2.5-fold reduction and ID3 showed a 3.5-fold induction in expression in response to PTTG overexpression in vitro. Conversely, suppression of PTTG with small interfering RNA was associated with a 2-fold induction of TSP-1 and a 2.2-fold reduction in ID3 expression. When we examined TSP-1 and ID3 expression in 34 differentiated thyroid cancers, ID3 was significantly increased in tumors compared with normal thyroid tissue. Furthermore, ID3 expression was significantly higher in follicular thyroid tumors than in papillary tumors. Although mean TSP-1 expression was not altered in cancers compared with normal thyroids, we observed a significant independent association between TSP-1 expression and early tumor recurrence, with recurrent tumors demonstrating 4.2-fold lower TSP-1 expression than normal thyroid tissues. CONCLUSION: We have identified ID3 and TSP-1 as two new downstream targets of PTTG in thyroid cancer. We propose that PTTG may promote angiogenesis by regulating the expression of multiple genes with both pro- and antiangiogenic properties and may thus be a key gene in triggering the angiogenic switch in thyroid tumorigenesis.
CONTEXT: Pituitary tumor-transforming gene (PTTG) is a multifunctional protein involved in several tumorigenic mechanisms, including angiogenesis. PTTG has been shown to promote angiogenesis, a key rate-limiting step in tumor progression, by up-regulation of fibroblast growth factor-2 and vascular endothelial growth factor. OBJECTIVE: To investigate whether PTTG regulates other angiogenic genes in thyroid cells, we performed angiogenesis-specific cDNA arrays after PTTG transfection. Two of the genes [inhibitor of DNA binding-3 (ID3) and thrombospondin-1 (TSP-1)] which showed differential expression in primary thyroid cells were validated in vitro and in vivo. RESULTS:TSP-1 showed a 2.5-fold reduction and ID3 showed a 3.5-fold induction in expression in response to PTTG overexpression in vitro. Conversely, suppression of PTTG with small interfering RNA was associated with a 2-fold induction of TSP-1 and a 2.2-fold reduction in ID3 expression. When we examined TSP-1 and ID3 expression in 34 differentiated thyroid cancers, ID3 was significantly increased in tumors compared with normal thyroid tissue. Furthermore, ID3 expression was significantly higher in follicular thyroid tumors than in papillary tumors. Although mean TSP-1 expression was not altered in cancers compared with normal thyroids, we observed a significant independent association between TSP-1 expression and early tumor recurrence, with recurrent tumors demonstrating 4.2-fold lower TSP-1 expression than normal thyroid tissues. CONCLUSION: We have identified ID3 and TSP-1 as two new downstream targets of PTTG in thyroid cancer. We propose that PTTG may promote angiogenesis by regulating the expression of multiple genes with both pro- and antiangiogenic properties and may thus be a key gene in triggering the angiogenic switch in thyroid tumorigenesis.
Authors: Rachel J Watkins; Martin L Read; Vicki E Smith; Neil Sharma; Gary M Reynolds; Laura Buckley; Craig Doig; Moray J Campbell; Greg Lewy; Margaret C Eggo; Laurence S Loubiere; Jayne A Franklyn; Kristien Boelaert; Christopher J McCabe Journal: Cancer Res Date: 2010-04-20 Impact factor: 12.701
Authors: Bin Zhu; Ming Gao; Lei Zhang; Juan Wang; Lei Wang; Ling Ling Qin; Xi Xiong Kang; Zhi Gang Zhao Journal: Metab Brain Dis Date: 2019-01-03 Impact factor: 3.584
Authors: S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke Journal: Endocrine Date: 2007-04 Impact factor: 3.633
Authors: Tetsuo Ito; Yutaka Shimada; Takatsugu Kan; Stefan David; Yulan Cheng; Yuriko Mori; Rachana Agarwal; Bogdan Paun; Zhe Jin; Alexandru Olaru; James P Hamilton; Jian Yang; John M Abraham; Stephen J Meltzer; Fumiaki Sato Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: S Hoffmann; S Gläser; A Wunderlich; S Lingelbach; C Dietrich; A Burchert; H Müller; M Rothmund; A Zielke Journal: Langenbecks Arch Surg Date: 2006-10-12 Impact factor: 3.445
Authors: Georges Said; Marie Guilbert; Hamid Morjani; Roselyne Garnotel; Pierre Jeannesson; Hassan El Btaouri Journal: Chemother Res Pract Date: 2012-07-01